Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Immuneering is raising $20,000,003.00 in new funding. Sources indicate as part of senior management President, Benjamin Zeskind played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Immuneering

Immuneering leverages more than a decade of leadership in bioinformatics to develop new medicines unlikely to be found by traditional drug discovery methods. Its current pipeline of drug candidates is focused on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. Utilizing its proprietary Disease Cancelling Technology, the company engineers medicines that reverse a disease signal across many relevant genes. Immuneering’s technologies have proven exceptionally rapid and capital-efficient in creating its pipeline. Concurrent with its internal programs, the company provides unparalleled computational biology services to leading pharmaceutical and biotechnology companies.

To learn more about Immuneering, visit http://immuneering.com/

Contact:
Benjamin Zeskind, President
617-500-8080
bzeskind@immuneering.com
https://www.linkedin.com/in/bzeskind/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved